European School of Haematology

0:03:34

Video 2 European School of Haematology (ESH)

0:04:22

Video 3 European School of Haematology (ESH)

0:04:59

Video 1 European School of Haematology (ESH)

0:04:13

Пост-ESH (European School of Haematology)

0:01:14

An overview of 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias

0:06:51

T cell development and T cell leukaemia

0:02:38

An overview of a session on treatment optimization in CML

0:01:15

The potential of differentiation therapies for AML

0:07:15

Master pathways and targets in T cell acute lymphoblastic leukaemia

0:01:40

Early detection and intervention in myeloma: a critical point

4:02:12

Пост-ESH (European School of Haematology)

0:01:21

MRD sequencing test approved for MM in the US

0:03:29

What is new for MDS with del(5q)?

0:02:50

The prognostic and therapeutic implications of TP53 expression in CMML

0:02:13

Collaboration and cooperation in hematology-oncology research

0:02:34

Using CAR T cells for the treatment of acute lymphoblastic leukaemia

0:04:17

Highlights from ICALL 2019

0:02:48

MRD and disease eradication in myeloma

0:01:14

Where will we be in MM management 5 years from now?

0:02:12

The Phase II HALF study: investigating a gradual TKI treatment discontinuation strategy in CML

0:02:07

Whole genome sequencing opens door for targeted Waldenström’s therapy

0:06:31

Precision diagnosis for tailored therapy in acute lymphoblastic leukaemia

0:05:37

The most promising therapeutic approaches currently being investigated for CMML

0:02:24

Judging the value of a clinical trial in hem-onc